Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > ocular inflammation treatment market
Get a free sample of Ocular Inflammation Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Ocular Inflammation Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The ocular inflammation treatment industry is fragmented in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products with improved efficiency and cost-effectiveness is among a key market strategy for ocular inflammation treatment product manufacturers.
Some of the eminent market participants operating in the ocular inflammation treatment industry include:
The market size of ocular inflammation treatment reached USD 7.5 billion in 2023 and is set to cross USD 11.4 billion by 2032, propelled by growing incidence of ocular inflammation and related complications coupled with rising expenditure on the R&D of novel treatments.
The corticosteroids segment was valued at over USD 1.9 billion in revenue in 2023, owing to the ability to suppress immune responses.
North America market recorded around USD 3 billion in revenue in 2023, attributed to robust healthcare infrastructure, extensive R&D initiatives, and a high prevalence of ocular inflammatory conditions.
AbbVie Inc., Alimera Sciences, Bausch Health Companies Inc., EyePoint Pharmaceuticals, Inc., Novartis AG, Ocular Therapeutix, Inc., Pfizer Inc., and Santen Pharmaceutical Co., Ltd.